Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01482962
Registration number
NCT01482962
Ethics application status
Date submitted
28/11/2011
Date registered
1/12/2011
Date last updated
31/07/2018
Titles & IDs
Public title
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Query!
Scientific title
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Query!
Secondary ID [1]
0
0
2011-003545-18
Query!
Secondary ID [2]
0
0
C14012
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsed Peripheral T-Cell Lymphoma
0
0
Query!
Refractory Peripheral T-Cell Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Alisertib
Treatment: Drugs - Pralatrexate
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Romidepsin
Experimental: Alisertib - Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
Active comparator: Pralatrexate, or Romidepsin, or Gemcitabine - Pralatrexate 30 mg/m\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
Treatment: Drugs: Alisertib
Alisertib enteric coated tablets
Treatment: Drugs: Pralatrexate
Pralatrexate IV infusion
Treatment: Drugs: Gemcitabine
Gemcitabine IV infusion
Treatment: Drugs: Romidepsin
Romidepsin IV infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of participants who achieve Complete Response (CR) or Partial Response (PR) as assessed by the IRC using International Working Group (IWG) criteria. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites.
Query!
Timepoint [1]
0
0
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Query!
Primary outcome [2]
0
0
Progression-Free Survival (PFS) Based on IRC Assessment
Query!
Assessment method [2]
0
0
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first.
Query!
Timepoint [2]
0
0
Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.
Query!
Timepoint [1]
0
0
Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)
Query!
Secondary outcome [2]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/ birth defect or is a medically important event.
Query!
Timepoint [2]
0
0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Query!
Secondary outcome [3]
0
0
Number of Participants With Clinically Important Abnormal Laboratory Values Reported as AEs
Query!
Assessment method [3]
0
0
Clinical laboratory tests included chemistry, hematology and urinalysis test. Clinically significant treatment-emergent laboratory abnormalities were reported by the investigator as TEAEs.
Query!
Timepoint [3]
0
0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Query!
Secondary outcome [4]
0
0
Number of Participants With Clinically Important Vital Sign Measurements Reported as AEs
Query!
Assessment method [4]
0
0
Vital signs included blood pressure, heart rate and temperature. Individual clinically significant changes in vital signs were reported by the investigator as TEAEs.
Query!
Timepoint [4]
0
0
First dose to 30 days after last dose of study drug or comparator (Up to 152 Weeks)
Query!
Secondary outcome [5]
0
0
Complete Response (CR) Rate
Query!
Assessment method [5]
0
0
Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.
Query!
Timepoint [5]
0
0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)
Query!
Secondary outcome [6]
0
0
Time to Disease Progression (TTP)
Query!
Assessment method [6]
0
0
Time to Progression (TTP) was defined as the time from the date of randomization to the date of first documentation of PD/relapse.
Query!
Timepoint [6]
0
0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Query!
Secondary outcome [7]
0
0
Duration of Response (DOR)
Query!
Assessment method [7]
0
0
DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD)/relapse for responders as assessed by the IRC using IWG criteria. Responders without documentation of PD/relapse were censored at the date of last response assessment that was stable disease (SD) or better.
Query!
Timepoint [7]
0
0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Query!
Secondary outcome [8]
0
0
Time to Response
Query!
Assessment method [8]
0
0
Time to Response is defined as the time from the date of randomization to the date of first documentation of PR or better.
Query!
Timepoint [8]
0
0
At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Query!
Secondary outcome [9]
0
0
Time to Subsequent Antineoplastic Therapy
Query!
Assessment method [9]
0
0
Time to subsequent antineoplastic therapy was defined as the time from randomization to the first date of subsequent antineoplastic therapy (excluding transplant). Participants without subsequent antineoplastic therapy were censored at the date of death or last known to be alive.
Query!
Timepoint [9]
0
0
From date of last study drug to date of subsequent antineoplastic therapy, if required; approximately 3 years
Query!
Secondary outcome [10]
0
0
Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.
Query!
Secondary outcome [11]
0
0
Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms
Query!
Assessment method [11]
0
0
The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.
Query!
Timepoint [11]
0
0
Baseline and End of Treatment (EOT) (Up to 152 Weeks)
Query!
Eligibility
Key inclusion criteria
* Male or female participants age 18 or older
* Participants with Peripheral T cell lymphoma (PTCL) (selected subtypes) according to World Health Organization (WHO) criteria and have relapsed or are refractory to at least 1 prior systemic, cytotoxic therapy for PTCL. Participants must have received conventional therapy as a prior therapy. Cutaneous-only disease is not permitted. Participants must have documented evidence of progressive and measurable disease.
* Tumor biopsy available for central hematopathologic review
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Female participants who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of contraception through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse.
* Male participants who agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse
* Suitable venous access
* Voluntary written consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
* Known central nervous system lymphoma
* Systemic antineoplastic therapy, immunotherapy, investigational agent or radiation therapy within 4 weeks of first dose of study treatment or concomitant use during study
* Prior administration of an Aurora A kinase-targeted agent, including alisertib; or all of the 3 comparator drugs (pralatrexate, or romidepsin or gemcitabine; or known hypersensitivity)
* History of uncontrolled sleep apnea syndrome or other conditions that could result in excessive daytime sleepiness
* Cardiac condition as specified in study protocol, including left ventricular ejection fraction (LVEF) <40%
* Concomitant use of other medicines as specified in study protocol
* Participants with abnormal gastric or bowel function who require continuous treatment with H2-receptor antagonists or proton pump inhibitors
* Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C
* Autologous stem cell transplant less than 3 months prior to enrollment
* Participants who have undergone allogeneic stem cell or organ transplantation any time
* Inadequate blood levels, bone marrow or other organ function as specified in study protocol
* The participant must have recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade = 1 toxicity, to participant's baseline status (except alopecia), or deemed irreversible from the effects of prior cancer therapy
* Major surgery, serious infection, or infection requiring systemic antibiotic therapy within 14 days prior to the first dose of study treatment
* Female participants who are breastfeeding or pregnant
* Coexistent second malignancy or history of prior solid organ malignancy within previous 3 years
* Serious medical or psychiatric illness or laboratory abnormality that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/12/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
271
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Concord
Query!
Recruitment hospital [3]
0
0
- Gosford
Query!
Recruitment hospital [4]
0
0
- Hobart
Query!
Recruitment hospital [5]
0
0
- St Leonards
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Concord
Query!
Recruitment postcode(s) [3]
0
0
- Gosford
Query!
Recruitment postcode(s) [4]
0
0
- Hobart
Query!
Recruitment postcode(s) [5]
0
0
- St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Hampshire
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Vermont
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
West Virginia
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Graz
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Innsbruck
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Salzburg
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Wien
Query!
Country [24]
0
0
Belarus
Query!
State/province [24]
0
0
Minsk Didtrict
Query!
Country [25]
0
0
Belarus
Query!
State/province [25]
0
0
Vitebsk
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Brugge
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Brussels
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Gent
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Kortrijk
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Turnhout
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Yvoir
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Belo Horizonte
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Campianas
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Caxias Do Sul
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Curitiba
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Goiania
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Porto Alegre/rs
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Porto Alegre
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Rio de Janeiro
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Salvador
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
SAO Paulo - SP
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Sao Paulo
Query!
Country [43]
0
0
Bulgaria
Query!
State/province [43]
0
0
Pleven
Query!
Country [44]
0
0
Bulgaria
Query!
State/province [44]
0
0
Sofia
Query!
Country [45]
0
0
Bulgaria
Query!
State/province [45]
0
0
Varna
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Ontario
Query!
Country [47]
0
0
Chile
Query!
State/province [47]
0
0
Concepcion
Query!
Country [48]
0
0
Chile
Query!
State/province [48]
0
0
Santiago
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Praha 2
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Arhus C
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Kobenhavn O
Query!
Country [52]
0
0
Egypt
Query!
State/province [52]
0
0
Alexandria
Query!
Country [53]
0
0
Egypt
Query!
State/province [53]
0
0
Beni Swef
Query!
Country [54]
0
0
Egypt
Query!
State/province [54]
0
0
Cairo
Query!
Country [55]
0
0
Egypt
Query!
State/province [55]
0
0
Dakahlia
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Bordeaux
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Marseille
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Paris
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Pessac
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Pierre Benite
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Tours
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Berlin
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Essen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Freiburg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Goettingen
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Homburg/saar
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Mainz
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Muenchen
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Munchen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
ULM
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Budapest
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Debrecen
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Kaposvar
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Pecs
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Beer-sheva
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Haifa
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Jerusalem
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Petach Tikva
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Ramat-gan
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Tel Aviv
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Bari
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Bologna
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Cagliari
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Firenze
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Meldola
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Modena
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Ravenna
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Rimini
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Roma
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Torino
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Durango Durango
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Mexico
Query!
Country [93]
0
0
Mexico
Query!
State/province [93]
0
0
Monterrey Nuevo LEON
Query!
Country [94]
0
0
Mexico
Query!
State/province [94]
0
0
Monterrey
Query!
Country [95]
0
0
Mexico
Query!
State/province [95]
0
0
San Luis Potosi
Query!
Country [96]
0
0
Netherlands
Query!
State/province [96]
0
0
Maastricht
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Nieuwegein
Query!
Country [98]
0
0
New Zealand
Query!
State/province [98]
0
0
Auckland
Query!
Country [99]
0
0
New Zealand
Query!
State/province [99]
0
0
Christchurch
Query!
Country [100]
0
0
New Zealand
Query!
State/province [100]
0
0
Takapuna
Query!
Country [101]
0
0
Peru
Query!
State/province [101]
0
0
Arequipa
Query!
Country [102]
0
0
Peru
Query!
State/province [102]
0
0
Lima
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Bydgoszcz
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Chorzow
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Krakow
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Lodz
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Warszawa
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Wroclaw
Query!
Country [109]
0
0
Portugal
Query!
State/province [109]
0
0
Braga
Query!
Country [110]
0
0
Portugal
Query!
State/province [110]
0
0
Coimbra
Query!
Country [111]
0
0
Portugal
Query!
State/province [111]
0
0
Porto
Query!
Country [112]
0
0
Puerto Rico
Query!
State/province [112]
0
0
San Juan
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Bucuresti
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Chelyabinsk
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Moscow
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
Petrozavodsk
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
St Petersburg
Query!
Country [118]
0
0
Slovakia
Query!
State/province [118]
0
0
Bratislava
Query!
Country [119]
0
0
Slovakia
Query!
State/province [119]
0
0
Martin
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Barcelona
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Girona
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Madrid
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Pamplona
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Salamanca
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Sevilla
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Valencia
Query!
Country [127]
0
0
Sweden
Query!
State/province [127]
0
0
Linkoping
Query!
Country [128]
0
0
Sweden
Query!
State/province [128]
0
0
Lund
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Solna
Query!
Country [130]
0
0
Turkey
Query!
State/province [130]
0
0
Ankara
Query!
Country [131]
0
0
Turkey
Query!
State/province [131]
0
0
Denizli
Query!
Country [132]
0
0
Turkey
Query!
State/province [132]
0
0
Istanbul
Query!
Country [133]
0
0
Turkey
Query!
State/province [133]
0
0
Kayseri
Query!
Country [134]
0
0
Turkey
Query!
State/province [134]
0
0
Samsun
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Birmingham
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Cardiff
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Liverpool
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Manchester
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
Newcastle Upon Tyne
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Southampton
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Truro
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Millennium Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01482962
Query!
Trial related presentations / publications
O'Connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trumper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Takeda Oncology
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01482962
Download to PDF